EW Total debt
Total debt at Edwards Lifesciences rose to $598M in fiscal 2025, the highest in the 5 years reported, from $598M in 2024.
Current debt plus long-term debt, both as filed. Names that do not tag current debt show long-term debt only, and say so.
SOURCE: us-gaap:LongTermDebtNoncurrent + us-gaap:LongTermDebtCurrent · EDGAR CompanyFacts · CIK 1099800 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Current debt | Long-term debt | Total |
|---|---|---|---|
| FY2025 | — | $598M | $598M |
| FY2024 | — | $598M | $598M |
| FY2023 | — | $597M | $597M |
| FY2022 | — | $596M | $596M |
| FY2021 | — | $596M | $596M |
More SAME DATA, OTHER VIEWS
Total debt across coverage → · EW company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.